Low blood levels of C3 protein at time of diagnosis are associated with poorer outcomes in patients with anti-neutrophil cytoplasmic…
Articles by Iqra Mumal, MSc
RIPK1 inhibitors may one day treat patients with antineutrophil cytoplasmic antibody (ANCA)-induced vasculitis (AAV), a new study finds. The study,…
Dr. Ronald J. Falk, chair of the department of medicine at the University of North Carolina and director of the UNC…
Members of the U.K.-based European Vasculitis Society (EUVAS) have accepted recently published recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis…
About a fifth of ANCA-associated vasculitis patients have an eye disorder known as inflammatory ocular disease, a Mayo Clinic study shows. The…
The protein TIMP1 is a promising biomarker of ANCA-associated vasculitis activity, according to a Japanese study that also identified markers…
Low levels of adenosine-regulating cell surface proteins on T-cells of patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis may contribute to…
International collaboration on research into rare diseases like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is fundamental to improving the health and…
Patients with eosinophilic granulomatosis with polyangiitis (EGPA, or Churg-Strauss syndrome) who receive scheduled Rituxan (rituximab) therapy have lower relapse rates…